327 related articles for article (PubMed ID: 37409550)
1. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Ezeaka UC; Kim HJJ; Laprairie RB
Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
[TBL] [Abstract][Full Text] [Related]
2. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
3. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?
Whelan A; Johnson MI
Pain Manag; 2018 May; 8(3):217-229. PubMed ID: 29722608
[TBL] [Abstract][Full Text] [Related]
4. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
[TBL] [Abstract][Full Text] [Related]
5. [Classic psychedelic drugs and their potential therapeutic effect].
Bayat M
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
7. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into psychedelic drug action.
Slocum ST; DiBerto JF; Roth BL
J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
[TBL] [Abstract][Full Text] [Related]
9. Comparison of psilocin with psilocybin, mescaline and LSD-25.
WOLBACH AB; MINER EJ; ISBELL H
Psychopharmacologia; 1962; 3():219-23. PubMed ID: 14007905
[No Abstract] [Full Text] [Related]
10. Human behavioral pharmacology of psychedelics.
Strickland JC; Johnson MW
Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
[TBL] [Abstract][Full Text] [Related]
11. Dosing Psychedelics and MDMA.
Liechti ME; Holze F
Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
[TBL] [Abstract][Full Text] [Related]
13. Response of cluster headache to psilocybin and LSD.
Sewell RA; Halpern JH; Pope HG
Neurology; 2006 Jun; 66(12):1920-2. PubMed ID: 16801660
[TBL] [Abstract][Full Text] [Related]
14. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
15. The promises and perils of psychedelic pharmacology for psychiatry.
McClure-Begley TD; Roth BL
Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
[TBL] [Abstract][Full Text] [Related]
16. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
Sousa TR; Rema J; Machado S; Novais F
Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
[TBL] [Abstract][Full Text] [Related]
17. Analysis of recreational psychedelic substance use experiences classified by substance.
Hase A; Erdmann M; Limbach V; Hasler G
Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
[TBL] [Abstract][Full Text] [Related]
18. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
19. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
[TBL] [Abstract][Full Text] [Related]
20. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits.
Videira NB; Nair V; Paquet V; Calhoun D
J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
